Sitagliptin add-on therapy cost saving for T2DM in Italy

Sitagliptin add-on therapy cost saving for T2DM in Italy PharmacoEconomics & Outcomes News 792, p28 - 2 Dec 2017 Sitagliptin add-on therapy cost saving for T2DM in Italy Sitagliptin added on to metformin is a cost-saving alternative to sulfonylurea add-on therapy for the management of patients with type 2 diabetes mellitus (T2DM) in Italy. This is the main finding of a cost-consequence analysis conducted to assess the economic impact of using sitagliptin, compared with sulfonylureas, as second-line therapy in add-on to metformin for a hypothetical cohort of 100 000 patients with T2DM not achieving glycaemic control with metformin monotherapy. The analysis was conducted from the Italian National Health Service (INHS) and a societal perspective. The data analysis showed that use of sitagliptin as add-on to metformin was cost saving from both the INHS and a societal perspective, generating savings of €51 846 442 and €61 217 723, respectively, over a 3-year time horizon. The researchers note that the higher drug acquisition costs related to sitagliptin + metformin therapy (€83 387 970) were offset by other costs for disease management at 3 years of follow-up, in particular due to lower use of devices for blood glucose self-monitoring, a lower incidence of hypoglycaemia and cardiovascular (CV) events, and a delay to insulin switch. The analysis also showed that use of sitagliptin would avoid 26 882 non-severe hypoglycaemic events, 6528 severe hypoglycaemic events and 1562 major CV events. * The study was supported by Merck Sharp & Dohme. Lorenzoni V, et al. Cost-consequence analysis of sitagliptin versus sulfonylureas as add-on therapy for the treatment of diabetic patients in Italy. ClinicoEconomics and Outcomes Research : 20 Nov 2017. Available from: URL: https:// doi.org/10.2147/CEOR.S141477 803285955 1173-5503/17/0792-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Dec 2017 No. 792 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png PharmacoEconomics & Outcomes News Springer Journals

Sitagliptin add-on therapy cost saving for T2DM in Italy

Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/sitagliptin-add-on-therapy-cost-saving-for-t2dm-in-italy-fP2gXsRgLD
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Pharmacoeconomics and Health Outcomes; Quality of Life Research; Health Economics; Public Health
ISSN
1173-5503
eISSN
1179-2043
D.O.I.
10.1007/s40274-017-4551-1
Publisher site
See Article on Publisher Site

Abstract

PharmacoEconomics & Outcomes News 792, p28 - 2 Dec 2017 Sitagliptin add-on therapy cost saving for T2DM in Italy Sitagliptin added on to metformin is a cost-saving alternative to sulfonylurea add-on therapy for the management of patients with type 2 diabetes mellitus (T2DM) in Italy. This is the main finding of a cost-consequence analysis conducted to assess the economic impact of using sitagliptin, compared with sulfonylureas, as second-line therapy in add-on to metformin for a hypothetical cohort of 100 000 patients with T2DM not achieving glycaemic control with metformin monotherapy. The analysis was conducted from the Italian National Health Service (INHS) and a societal perspective. The data analysis showed that use of sitagliptin as add-on to metformin was cost saving from both the INHS and a societal perspective, generating savings of €51 846 442 and €61 217 723, respectively, over a 3-year time horizon. The researchers note that the higher drug acquisition costs related to sitagliptin + metformin therapy (€83 387 970) were offset by other costs for disease management at 3 years of follow-up, in particular due to lower use of devices for blood glucose self-monitoring, a lower incidence of hypoglycaemia and cardiovascular (CV) events, and a delay to insulin switch. The analysis also showed that use of sitagliptin would avoid 26 882 non-severe hypoglycaemic events, 6528 severe hypoglycaemic events and 1562 major CV events. * The study was supported by Merck Sharp & Dohme. Lorenzoni V, et al. Cost-consequence analysis of sitagliptin versus sulfonylureas as add-on therapy for the treatment of diabetic patients in Italy. ClinicoEconomics and Outcomes Research : 20 Nov 2017. Available from: URL: https:// doi.org/10.2147/CEOR.S141477 803285955 1173-5503/17/0792-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Dec 2017 No. 792

Journal

PharmacoEconomics & Outcomes NewsSpringer Journals

Published: Dec 2, 2017

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve Freelancer

DeepDyve Pro

Price
FREE
$49/month

$360/year
Save searches from
Google Scholar,
PubMed
Create lists to
organize your research
Export lists, citations
Read DeepDyve articles
Abstract access only
Unlimited access to over
18 million full-text articles
Print
20 pages/month
PDF Discount
20% off